Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Toripalimab Injection (Pd-1 Antibody) With Cisplatin Concurrent IMRT for Local Advanced Cervical Cancer.

NCT04368273 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT04368273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04368273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Toripalimab Injection (Pd-1 Antibody) With Cisplatin Concurrent IMRT for Local Advanced Cervical Cancer.
Lead sponsor
Peking University Third Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 8, 2020
Completion date
December 31, 2022
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer